 | |
| Clinical data | |
|---|---|
| Other names | MT-3995 |
| Routes of administration | Oral |
| Drug class | Antimineralocorticoid |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C17H17FN2O4S |
| Molar mass | 364.39 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Apararenone (INN; development codeMT-3995) is anonsteroidalantimineralocorticoid which is under development byMitsubishi Tanabe Pharma for the treatment ofdiabetic nephropathies andnon-alcoholic steatohepatitis.[1][2][3] It was also previously being developed for the treatment ofhypertension, but development was discontinued for this indication.[1] Apararenone acts as a highlyselectiveantagonist of themineralocorticoid receptor (Ki < 50 nM), thereceptor foraldosterone.[1][2][3] As of 2017, it is inphase IIclinical trials.[1]
 | Thisdrug article relating to thecardiovascular system is astub. You can help Wikipedia byexpanding it. |